Genomatica

Genomatica was founded in 1998 and is based in San Diego, California. It's a global leader in bioprocess development, specifically in scaling-up fermentation-based production platforms from lab and pilot operations to commercial production. The company develops bioprocesses and bio-based chemicals that can directly compete with and replace thermocatalytic processes and petrochemicals. Customers realize gains on important metrics including overall cost, size of production facility, and stability of the final chemical product.

Genomatica is a global leader in bioprocess development, specifically in scaling-up fermentation-based production platforms from lab and pilot operations to commercial production. The company develops bioprocesses and bio-based chemicals that can directly compete with and replace thermocatalytic processes and petrochemicals. Customers realize gains on important metrics including overall cost, size of production facility, and stability of the final chemical product. The company was founded in 1998 and is headquartered in San Diego, California.

Genomatica was founded in 1998 and is based in San Diego, California. It's a global leader in bioprocess development, specifically in scaling-up fermentation-based production platforms from lab and pilot operations to commercial production. The company develops bioprocesses and bio-based chemicals that can directly compete with and replace thermocatalytic processes and petrochemicals. Customers realize gains on important metrics including overall cost, size of production facility, and stability of the final chemical product.

Genomatica was founded in 1998 and is based in San Diego, California. It's a global leader in bioprocess development, specifically in scaling-up fermentation-based production platforms from pilot operations to commercial production. The company develops bioprocesses and bio-based chemicals that can directly compete with and replace thermocatalytic processes and petrochemicals. Customers realize gains on important metrics including overall cost, size of production facility, and stability of the final chemical product.

Genomatica has developed a novel commercial bioprocess for 1,4-butanediol (BDO) marketed as GENO BDO. It is a major chemical intermediate that can be used to manufacture polymers for applications in athletic apparel, electronics substrates, and automotive materials. The technology package for the bioprocess is licensed to Novamont, which operates a 30,000 metric ton per year facility in Bottrighe (Adria), Italy. GENO BDO is also licensed to BASF.

Genomatica has developed a novel commercial bioprocess for 1,3-butylene glycol (BG) marketed as Brontide BG. It is a specialty chemical with applications in cosmetics and personal care products. The company supplies the product to various brands, including Bio-Bontanica, Azelis, and Daicel.

Genomatica is developing novel commercial bioprocesses for polyamide intermediates such as hexamethylenediamine (HMD), caprolactam (CPL), and adipic acid (ADA). The chemical family can be used to manufacture nylon 6; nylon 6,6; and polyurethanes; which have applications in apparel, carpets, miscellaneous fibers, and engineering plastics. Each polyamide intermediate offers specific advantages over incumbent petrochemicals, including up to 40% cost reductions, lower off-gassing and improved stability, smaller production facilities, fewer process steps, and improved process safety.

Genomatica is developing a novel commercial bioprocess for butadiene (BDE) with commercial partners ENI Versalis and Braskem. The chemical has applications in tires, polymers, latex, asphalt, and others; and can be used directly for styrene butadiene rubber. The global annual market exceeds 9 million metric tons. In 2015, Genomatica and Braskem confirmed the lab-scale development of a single-step process for directly converting agricultural sugars to BDE, which could enable significant cost reductions over existing two-step petrochemical processes.